Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of phage medicines on tackling (a) recurrent and chronic urinary tract infections and (b) associated antimicrobial resistance.

The Department recognises bacteriophage, or phage, medicines as a promising complementary option for difficult bacterial infections, including recurrent and chronic urinary tract infections (UTIs), and as a potential tool to address antimicrobial resistance (AMR).

However, phage therapy is not yet used routinely in the National Health Service. Although case reports and small studies show benefit in hard-to-treat infections, there is still insufficient largescale, high-quality clinical trial evidence to support widespread adoption.

For UTIs specifically, there is currently no evidence of benefit of phage therapy from randomised controlled trials, the only trial to date showed no effect. The proposed UK Clinical Phage Service will help generate further clinical evidence and support individual patient use where treatment options are limited.

As a result, phage therapy in the United Kingdom is generally accessed only through specialist or compassionate use pathways, typically when conventional antibiotics have failed and expert clinical teams judge it appropriate. This cautious approach ensures appropriate safety, efficacy, and regulatory oversight before routine use.